Part 1 - Case Presentation

Brian A. Jonas, MD, PhD, FACP, presents the case of patient “J.S.” to fellow faculty members Daniel A. Pollyea, MD, MS, and Gabriel N. Mannis, MD. The virtual roundtable panel discusses unique features of the case and explores hypothetical variations of the circumstances, as well as offering insights into how the latest data from clinical trials may impact the future of treatment for patients with acute myeloid leukemia (AML).

Click here to learn more by viewing Part 2 - Case Discussion.

Disclosures:

Brian A. Jonas, MD, PhD, FACP
Consulting Fees: AbbVie, Genentech, GlycoMimetics, Jazz, Takeda
Contracted Research: 47, AbbVie, Amgen, AROG, Celgene, Daiichi-Sankyo, Forma, Genentech/Roche, GMI, Hanmi, Jazz, Pfizer, PCYC
Travel Reimbursement: AbbVie

Gabriel N. Mannis, MD
Consulting Fees: AbbVie, Agios, BMS/Celgene, Genentech, Pfizer
Contracted Research: Gilead/Forty Seven, Glycomimetics, Jazz

Daniel A. Pollyea, MD, MS
Consulting Fees: Celgene, Abbvie, Genentech, Novartis, Karyopharm, Syndax, BMS
Other: Takeda, Syros, Kiadis, Foghorn, Aprea, Gilead, Amgen, Astellas

References:

  1. Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med. 2017 Aug 3;377(5):454-464. doi: 10.1056/NEJMoa1614359. Epub 2017 Jun 23. PMID: 28644114; PMCID: PMC5754190.
  2. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28. PMID: 27895058; PMCID: PMC5291965.
  3. Döhner K, Thiede C, Jahn N, Panina E, Gambietz A, et al. Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood. 2020 Jan 30;135(5):371-380. doi: 10.1182/blood.2019002697. PMID: 31826241; PMCID: PMC6993016.
  4. Loghavi S, Zuo Z, Ravandi F, Kantarjian HM, Bueso-Ramos C, et al. Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations. J Hematol Oncol. 2014 Oct 4;7:74. doi:
    10.1186/s13045-014-0074-4. PMID: 25281355; PMCID: PMC4197326.
  5. Burchert A, Bug G, Fritz LV, Finke J, Stelljes M, et al. Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN). J Clin Oncol. 2020 Sep 10;38(26):2993-3002. doi: 10.1200/JCO.19.03345. Epub 2020 Jul 16. PMID: 32673171.